ATI INC. DL-,01/ US01741R1023 /
2024-05-08 8:21:10 PM | Chg. +0.64 | Volume | Bid8:50:12 PM | Ask8:50:12 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
56.38EUR | +1.15% | 0 Turnover: 0.00 |
-Bid Size: - | -Ask Size: - | 6.97 bill.EUR | - | - |
GlobeNewswire
05-07
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
03-27
William & Mary Campus Mass Notification Drill Using ATI Systems’ Mass Notification Solution
GlobeNewswire
03-12
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
GlobeNewswire
02-13
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
GlobeNewswire
02-06
Seoul Robotics to Pursue Initial Public Offering with Samsung Securities as it Expands OEM Partnersh...
GlobeNewswire
2023-12-27
Eco Bright Future, Inc. Announces Signing of "Letter-of-Intent" With United Heritage, Sociedad Anoni...
GlobeNewswire
2023-12-12
Astrotech Announces Exciting New Technology Application and Introduces New Subsidiary
GlobeNewswire
2023-11-13
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (AT...
GlobeNewswire
2023-11-06
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
GlobeNewswire
2023-10-27
Strategic Advisory Board Elevates sureti’s Property Claims Resolution Capabilities
GlobeNewswire
2023-10-25
Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT...
GlobeNewswire
2023-10-23
ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
GlobeNewswire
2023-10-19
Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV a...
GlobeNewswire
2023-10-03
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic De...
GlobeNewswire
2023-09-30
ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
GlobeNewswire
2023-09-19
ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
GlobeNewswire
2023-09-18
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-21...